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Summary
Glycogen-storage disease type 1 (GSD-1), also known
as “von Gierke disease,” is caused by a deficiency in
microsomal glucose-6-phosphatase (G6Pase) activity.
There are four distinct subgroups of this autosomal re-
cessive disorder: 1a, 1b, 1c, and 1d. All share the same
clinical manifestations, which are caused by abnormal-
ities in the metabolism of glucose-6-phosphate (G6P).
However, only GSD-1b patients suffer infectious com-
plications, which are due to both the heritable neutro-
penia and the functional deficiencies of neutrophils and
monocytes. Whereas G6Pase deficiency in GSD-1a pa-
tients arises from mutations in the G6Pase gene, this gene
is normal in GSD-1b patients, indicating a separate locus
for the disorder in the 1b subgroup. We now report the
linkage of the GSD-1b locus to genetic markers spanning
a 3-cM region on chromosome 11q23. Eventual molec-
ular characterization of this disease will provide new
insights into the genetic bases of G6P metabolism and
neutrophil-monocyte dysfunction.
Introduction
Neutrophil dysfunction and neutropenia contribute to
increased susceptibility to bacterial infection in a number
of clinical conditions, including the 1b subgroup of gly-
cogen-storage disease type 1 (GSD-1b; MIM 232220
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dispmim?232220]), mannosidosis, and Chediak-Higa-
shi, Schwachman-Diamond, hyperimmunoglobulin E,
and periodontitis syndromes (Gallin 1992; Anderson et
al. 1995). For these autosomal recessive diseases, an un-
derlying genetic defect in neutrophils has been impli-
cated, but the molecular mechanism is unknown. GSD-
1b, one of the four distinct subgroups of glycogen-stor-
age disease type 1 (GSD-1), offers a potential model for
exploring such mechanisms. GSD-1, also known as “von
Gierke disease,” is caused by a deficiency in microsomal
glucose-6-phosphatase (G6Pase) activity (Moses 1990;
Chen and Burchell 1995). In addition to GSD-1b, three
other GSD-1 subgroups—1a, 1c, and 1d—have been de-
scribed (Narisawa et al. 1978; Beaudet et al. 1980; Nor-
dlie et al. 1983; Chen and Burchell 1995). GSD-1a,
which represents 80%–90% of GSD-1 cases, is caused
by defects in the G6Pase gene, which is localized on
chromosome 17 (Lei et al. 1993, 1994). GSD-1b is the
second most prevalent form of GSD-1, and it is the most
severe (Narisawa et al. 1978; Beaudet et al. 1980; Chen
and Burchell 1995). It presents with the clinical mani-
festations of GSD-1, including fasting hypoglycemia, he-
patomegaly, growth retardation, lactic acidemia, hyper-
lipidemia, and hyperuricemia, that directly reflect the
defects in metabolism of glucose-6-phosphate (G6P)
(Chen and Burchell 1995). However, unlike other GSD-
1 subgroups, GSD-1b patients suffer additional infec-
tious complications that are due to the heritable neu-
tropenia and the functional deficiencies of neutrophils
and monocytes (Beaudet et al. 1980; Gitzelmann and
Bosshard 1993). These complications are not readily at-
tributable to the G6Pase deficiency. Identification of the
gene responsible for GSD-1b should, therefore, provide
insights into the genetic basis of neutrophil-monocyte
dysfunction and its link to G6P metabolism.
GSD-1b is inherited as an autosomal recessive dis-
order, with no obvious genetic heterogeneity (Chen and
Burchell 1995). Current treatments for GSD-1b consist
of the combination of dietary therapy (Fernandes et al.
1988; Chen and Burchell 1995), to correct symptoms of
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G6Pase deficiency, and human granulocyte-macrophage
colony-stimulating factor (GM-CSF) therapy (Roe et al.
1992; Wendel et al. 1993; Spiekermann et al. 1997).
GM-CSFs are humoral regulators of hematopoiesis that
increase both the proliferation of myeloid precursors and
the functional capacity of neutrophils (Golde and Bald-
win 1992). In GSD-1b patients, GM-CSF treatment in-
creases neutrophil counts and reduces the frequency of
infection and inflammation (Roe et al. 1992; Wendel et
al. 1993; Spiekermann et al. 1997), complications that
are not manageable by dietary therapy alone. This sug-
gests that neutrophil dysfunction associated with GSD-
1b is distinct from the defect in G6P metabolism.
In this study, we report a genetic analysis of the gene
that is deficient in GSD-1b patients. Highly informative
microsatellite markers map the GSD-1b locus to the long
arm of chromosome 11.
Subjects and Methods
Families
Eight consanguineous families (1–8) and one noncon-
sanguineous family (9) (fig. 1) were included in this
study. The ethnic origins of these families are Bedouin
(families 1, 2, and 4), North African (family 3), Pakistani
(family 5), Iranian Jewish (family 6), Israeli Arab (fam-
ilies 7 and 8), and European (family 9). These families
were chosen because all patients presented with the typ-
ical GSD-1 clinical manifestations: fasting hypoglyce-
mia, hepatomegaly, and growth retardation. All were
diagnosed as having GSD-1b on the basis of additional
symptoms: neutropenia, neutrophil dysfunction, recur-
rent bacterial infections, and the absence of a genetic
defect in the G6Pase gene.
Genomic DNA preparations were extracted from
blood samples by means of a Nucleon II kit (Scotlab
Bioscience). All peripheral blood samples were obtained
with the informed consent of the patients and/or their
parents.
Linkage Analysis
The high-density microsatellite markers kit, spanning
10–20-cM intervals of the genome (Human Linkage
Screening Set, version 8, from the Cooperative Human
Linkage Center), and additional, chromosome 11 mark-
ers were all obtained from Research Genetics. For initial
genomewide screening, two generations (IV and V) of
family 1, which has two affected siblings, were chosen.
Markers that were homozygous for the two affected in-
dividuals were then used to genotype the last two gen-
erations of the other eight families. DNA polymorphisms
were analyzed by means of PCR amplification of simple
sequence repeats. Reaction mixtures (20 ml) contained
20 mM Tris-HCl, pH 8.4; 50 mM KCl; 1.5–2.0 mM
MgCl2; 200 mM each of dATP, dGTP, and dTTP; 20 mM
dCTP; 2.5 mCi [32P]-dCTP (3,000 Ci/mmol); 1 mM each
primer; 100 ng genomic DNA; and 1 U Taq DNA poly-
merase. The PCR was performed for a total of 30 cycles
by use of a Perkin-Elmer 9600 Thermal Cycler. The am-
plified fragments were analyzed by electrophoresis
through standard DNA-sequencing gels.
Two-point linkage analysis was performed with
MLINK, and multipoint linkage analysis was performed
with LINKMAP (Lathrop et al. 1984; Dracopoli et al.
1995). The LOD score calculations assumed an auto-
somal recessive mode of inheritance with full penetrance,
no sex difference, no interference, a mutant gene fre-
quency of 1/100,000, and equal allele frequencies for
each marker.
Results
A total of 366 high-density microsatellite markers,
spaced at 10–20 cM and covering chromosomes 1–22,
were initially used to screen two generations (IV and V)
of consanguineous family 1 (fig. 1). Patients from con-
sanguineous matings are expected to be homozygous for
the disease locus and for its linked markers. Therefore,
markers that exhibited homozygosity were used to an-
alyze the other families. Marker D11S1998 on chro-
mosome 11q23 showed homozygosity across all pedi-
grees and yielded a LOD score of 6.882 at a
recombination fraction of (table 1). Additionalv  .00
markers mapping to this region supported the assign-
ment of the GSD-1b locus to chromosome 11q23 (table
1). Pairwise linkage analysis of all available members in
the nine families yielded LOD scores between 2.948 and
10.015, at , for markers D11S1340, D11S1998,v  .00
D11S939, D11S1356, D11S4104, D11S1341,
D11S976, D11S614, and D11S4129 (table 1).
The GSD-1b locus was identified, by use of the hap-
lotype data, in a genetic region of ∼3.6 cM, between
markers D11S1340 and D11S4129. We were able to
achieve the localization by examining for lack of ho-
mozygosity in affected individuals from consanguineous
families. Lack of homozygosity was observed in indi-
viduals V-4 and V-5, in family 1, for marker D11S1340
(fig. 1). Since the parents of V-4 and V-5 do not share
an allele for D11S1340, this recombination is considered
a historic one that must have occurred in previous gen-
erations. The distal recombination is again a historic one
and is observed in individual IV-3, in family 2, for
marker D11S4129 (fig. 1). The chromosomal order of
the markers used was adopted from the Genetic Lo-
cation Database (http://cedar.genetics.soton.ac.uk/
publichtml), provided by Collins et al. (1996). The es-
timated distances (in cM) between the analyzed markers
are given in table 1 and are shown schematically in figure
2. The haplotypes for the nine markers of the available
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Figure 1 Pedigrees of the nine GSD-1b families used in the linkage study. The haplotypes in loci D11S1340, D11S1998, D11S939,
D11S1356, D11S4104, D11S1341, D11S976, D11S614, and D11S4129 are given for each genotyped individual. Blackened symbols represent
affected individuals, and unblackened symbols represent unaffected individuals. Lack of homozygosity—observed in individuals V-4 and V-5,
in family 1, for marker D11S1340, and in individual IV-3, in family 2, for marker D11S4129—is indicated by an arrow.
family members are displayed in figure 1. A recombi-
nation in the genome of individual V-2, in family 1, and
individual V-6, in family 3 (fig. 1), placed the GSD-1b
locus distal to D11S939, refining its position to a 3.0-
cM region on chromosome 11q23, between markers
D11S939 and D11S4129 (fig. 2). The results are con-
sistent with transmission of GSD-1b as an autosomal
recessive trait (Chen and Burchell 1995) at a single locus.
Multipoint LOD-score analysis between markers
D11S938, D11S1340, D11S1998, D11S976, D11S614,
D11S4129, and D11S4107 and the disease locus placed
the GSD-1b gene between markers D11S1340 and
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Table 1
Two-Point LOD Scores between the GSD-1b Locus and Chromosome 11 Polymorphic
Markers, for Nine GSD-1b Families
LOD SCORE AT v 
MARKER LOCUS CM .00 .001 .01 .05 .1 .2 .3
D11S938 115.491 ∼ .430 1.486 2.425 2.362 1.615 .820
D11S1340 120.857 2.948 4.673 5.516 5.485 4.807 3.164 1.619
D11S1998 121.291 6.882 6.860 6.663 5.796 4.743 2.834 1.372
D11S939 121.378 6.094 6.073 5.881 5.042 4.038 2.280 1.018
D11S1356 121.900 8.713 8.688 8.459 7.442 6.186 3.831 1.932
D11S4104 123.222 7.052 7.031 6.851 6.047 5.056 3.207 1.704
D11S1341 123.363 7.962 7.937 7.712 6.716 5.502 3.289 1.586
D11S976 123.936 8.325 8.300 8.074 7.705 5.845 3.566 1.765
D11S614 124.114 10.015 9.987 9.735 8.612 7.217 4.568 2.368
D11S4129 124.421 7.068 7.046 6.849 5.980 4.922 2.987 1.459
D11S925 126.399 1.983 4.799 5.622 5.531 4.839 3.221 1.736
D11S4107 126.772 ∼ 4.517 5.369 5.333 4.644 3.000 1.536
NOTE.—Linkage analysis was performed with consanguinity loops included for all markers,
the allele frequencies were kept equal, and the LOD scores were calculated under the assumption
of an autosomal recessive trait of inheritance, with 100% penetrance.
Figure 2 The best-supported order and sex-averaged distances
(in cM) between the markers showing linkage to the GSD-1b locus.
The IL-10 receptor, Na/K-gATPase, and ALL-1 genes mapping to this
region are shown.
D11S4129, centered around D11S976, with a maximum
LOD score of 14.110 at (data not shown). It isv  .00
worth noting that the LINKMAP multipoint analysis
failed to exclude the positions of markers D11S1340 and
D11S4129 as candidate locations for the GSD-1b locus
because the recombinations are historic and are not seen
when only the parental haplotypes are examined.
Discussion
Using one nonconsanguineous and eight consanguin-
eous GSD-1b families, we have mapped the GSD-1b
gene locus to chromosome 11q23, between markers
DS11S939 and D11S4129, which define an interval of
∼3 cM. The results are consistent with transmission of
GSD-1b as an autosomal recessive trait (Chen and Bur-
chell 1995) at a single locus.
G6Pase is a membrane-spanning protein (Lei et al.
1993) localized in the endoplasmic reticulum (ER), with
the active site apparently facing into the lumen (Waddell
and Burchell 1991). Despite the functional G6Pase de-
ficiency in GSD-1b patients, the G6Pase gene in these
patients is normal (Lei et al. 1995), and high G6P hy-
drolytic activity is observed when the microsomal mem-
branes are disrupted (Narisawa et al. 1978; Lange et al.
1980). This observation, along with kinetic (Narisawa
et al. 1978; Arion et al. 1980; Lange et al. 1980) and
G6P-transport (Igarashi et al. 1984) studies, has implied
that the GSD-1b defect prevents uptake of G6P by the
intact microsomal membrane. In earlier work, we dem-
onstrated that the G6Pase gene, localized on chromo-
some 17 (Lei et al. 1994), is defective in GSD-1a patients
(Lei et al. 1993). Using G6Pase-deficient mice, we
showed that there is a tight functional dependence of
G6P transport on G6Pase activity (Lei et al. 1996). These
observations, taken in conjunction with the lack of ge-
netic heterogeneity in GSD-1b (Chen and Burchell
1995), strongly suggest that (1) transport and hydrolysis
of G6P involve only two proteins, (2) one of these com-
ponents is the G6Pase catalytic unit, and (3) the second
component, encoded by the GSD-1b gene, is an ER
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membrane–associated protein that either transports G6P
into the lumen or transduces a signal from the cytoplasm
into the lumen, triggering G6Pase to transport G6P.
How a G6P metabolic defect in GSD-1b can impair
chemotaxis, mobility, and respiratory-burst activity in
patients’ polymorphonuclear leukocytes (Kilpatrick et
al. 1990; Gitzelmann and Bosshard 1993), as well as
their ability to mobilize Ca2 in response to physiological
stimuli in neutrophils and monocytes, is unclear (Kil-
patrick et al. 1990). The G6Pase gene is expressed pri-
marily in the liver, kidney, intestine, and pancreas, but
it is not expressed in myeloid cells (Foster et al. 1997).
Indeed, liver allografts that correct the apparent G6P
metabolic deficiencies do not correct neutrophil dys-
function (Lachaux et al. 1993). Therefore, the defect
must be intrinsic to the cells of the myeloid lineage. Al-
though G6P has been shown to enhance Ca2 uptake by
microsomes (Benedetti et al. 1988) and although a role
for G6P in regulating microsomal Ca2 sequestration
and release has been suggested, Ca2-mediated events
cannot explain all respiratory-burst defects in patients
with GSD-1b (Kilpatrick et al. 1990). One possible ex-
planation lies in the ER location of the GSD-gene prod-
ucts. Although the signal transduced by the GSD-1b pro-
tein in the liver controls G6Pase activity, it may also be
used by the myeloid cells to modify the processing of
proteins passing through the ER, leading to the observed
dysfunction. It is interesting to note that chronic infusion
of GM-CSF, which increases neutrophil and monocyte
counts, improves the neutrophil-monocyte response in
GSD-1b patients (Roe et al. 1992; Wendel et al. 1993;
Spiekermann et al. 1997).
A survey of the expressed-sequence–tag database de-
scribes 160 transcribed sequences in the GSD-1b region
of interest. The genes of known function in this region
include the ALL-1 gene and those for Na/K-g-ATPase
and the interleukin-10 receptor (Gu et al. 1992) (fig. 2).
Since none of these genes encode proteins that are lo-
calized to the ER, are involved in carbohydrate metab-
olism, or are involved in signaling, the GSD-1b defect
must be an uncharacterized gene in this region. The link-
age of the GSD-1b locus to genetic markers on chro-
mosome 11q23 facilitates the positional cloning of the
gene, which should lead both to the elucidation of its
biological role and to an understanding of the interre-
lationship between G6P metabolism and neutrophil
function.
Acknowledgments
We thank all family members for their cooperation and for
donating blood samples for our study. We are grateful to Dr.
A. Feigenbaus and Ms. D. Anderson at the Hospital for Sick
Children, Toronto, for the coordination of family 5.
References
Anderson DC, Kishimoto TK, Smith CW (1995) Leukocyte
adhesion deficiency and other disorders of leukocyte adher-
ence and mobility. In: Scriver CR, Beaudet AL, Sly WS, Valle
D (eds) The metabolic and molecular bases of inherited dis-
ease, 7th ed. McGraw-Hill, New York, pp 3955–3994
Arion WJ, Lange AJ, Walls HE, Ballas LM (1980) Evidence
of the participation of independent translocases for phos-
phate and glucose-6-phosphate in the microsomal glucose-
6-phosphatase system. J Biol Chem 255:10396–10406
Beaudet AL, Anderson DC, Michels VV, Arion WJ, Lange AJ
(1980) Neutropenia and impaired neutrophil migration in
type 1B glycogen storage disease. J Pediatr 97:906–910
Benedetti A, Fulceri R, Romani A, Comporti M (1988)
MgATP-dependent glucose-6-phosphate-stimulated calcium
accumulation in liver microsomal fractions. J Biol Chem
263:3466–3473
Chen Y-T, Burchell A (1995) Glycogen storage diseases. In:
Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic
and molecular bases of inherited disease, 7th ed. McGraw-
Hill, New York, pp 935–965
Collins A, Frezal J, Teague J, Morton NE (1996) A metric map
of humans: 23,500 loci in 850 bands. Proc Natl Acad Sci
USA 93:14771–14775
Dracopoli NC, Haines JL, Korf BR, Moir DT, Morton CC,
Seidman CE, Seidman JG, et al (1995) Use of linkage pro-
grams for linkage analysis. In: Current protocols in human
genetics, John Wiley & Sons, Inc., unit 1.7, New York
Fernandes J, Leonard JV, Moses SW, Odievre M, di Rocco M,
Schaub J, Smit GPA, et al (1988) Glycogen storage disease:
recommendations for treatment. Eur J Pediatr 147:226–228
Foster JD, Pederson BA, Nordlie RC (1997) Glucose-6-phos-
phatases structure, regulation, and function: an update. Proc
Soc Exp Biol Med 215:314–332
Gallin JI (1992) Disorders of phagocytic cells. In: Gallin JI,
Goldstein IM, Snyderman R (eds) Inflammation: basic prin-
ciples and clinical correlates, 2d ed. Raven Press, New York,
pp 859–874
Gitzelmann R, Bosshard NU (1993) Defective neutrophil and
monocyte functions in glycogen storage disease type 1b: a
literature review. Eur J Pediatr 152, suppl 1:S33–S38
Golde DW, Baldwin GC (1992) Myeloid growth factors. In:
Gallin JI, Goldstein IM, Snyderman R (eds) Inflammation:
basic principles and clinical correlates, 2d ed. Raven Press,
New York, pp 291–301
Gu Y, Nakamura H, Alder H, Prasad R, Canaani O, Cimino
G, Croce CM, et al (1992) The t(4:11) chromosome trans-
location of human acute leukemias fuses the ALL-1 gene,
related to Drosophila trithorax, to the AF-4 gene. Cell 71:
701–708
Igarashi Y, Kato S, Narisawa K, Tada K (1984) A direct evi-
dence for defect in glucose-6-phosphatase transport system
in hepatic microsomal membrane of glycogen storage disease
type 1b. Biochem Biophys Res Commun 119:593–597
Kilpatrick L, Garty B-Z, Lundquist KF, Hunter K, Stanley CA,
Baker L, Douglas SD, et al (1990) Impaired metabolic func-
tion and signalling defects in phagocytic cells in glycogen
storage disease type 1b. J Clin Invest 86:196–202
Lachaux A, Boillot O, Stamm D, Canterino I, Dumontet C,
Annabi et al.: GSD-1b Locus Maps to 11q23 405
Regnier F, Floret D, et al (1993) Treatment with lenograstim
(glycosylated recombinant human granulocyte colony-stim-
ulating factor) and orthotopic liver transplantation for gly-
cogen storage disease type Ib. J Pediatr 123:1005–1008
Lange AJ, Arion WJ, Beaudet AL (1980) Type 1b glycogen
storage disease is caused by a defect in the glucose-6-phos-
phate translocase of the microsomal glucose-6-phosphatase
system. J Biol Chem 255:8381–8384
Lathrop GM, Lalouel JM, Julier C, Ott J (1984) Strategies for
multilocus linkage analysis in humans. Proc Natl Acad Sci
USA 81:3443–3446
Lei K-J, Chen Y-T, Pan C-J, Ward JM, Mosinger B, Lee EJ,
Westphal H, et al (1996) Glucose-6-phosphatase dependent
substrate transport in the glycogen storage disease type 1a
mouse. Nat Genet 13:203–209
Lei K-J, Pan C-J, Shelly LL, Liu J-L, Chou JY (1994) Identi-
fication of mutations in the gene for glucose-6-phosphatase,
the enzyme deficient in glycogen storage disease type 1a. J
Clin Invest 93:1994–1999
Lei K-J, Shelly LL, Lin B, Sidbury JB, Chen Y-T, Nordlie RC,
Chou JY (1995) Mutations in the glucose-6-phosphatase
gene are associated with glycogen storage disease type 1a
and 1aSP but not 1b and 1c. J Clin Invest 95:234–240
Lei K-J, Shelly LL, Pan C-J, Sidbury JB, Chou JY (1993) Mu-
tations in the glucose-6-phosphatase gene that cause gly-
cogen storage disease type 1a. Science 262:580–583
Moses SW (1990) Pathophysiology and dietary treatment of
the glycogen storage diseases. J Pediatr Gastroenterol Nutr
11:156–174
Narisawa K, Igarashi Y, Otomo H, Tada K (1978) A new
variant of glycogen storage disease type I probably due to
a defect in the glucose-6-phosphate transport system.
Biochem Biophys Res Commun 83:1360–1364
Nordlie RC, Sukalski KA, Munoz JM, Baldwin JJ (1983) Type
1c, a novel glycogenosis. J Biol Chem 258:9739–9744
Roe TF, Coates TD, Thomas DW, Miller JH, Gilsanz V (1992)
Treatment of chronic inflammatory bowel disease in gly-
cogen storage disease type Ib with colony-stimulating fac-
tors. N Engl J Med 326:1666–1669
Spiekermann K, Roesler J, Emmendoerffer A, Elsner J, Welte
K (1997) Functional features of neutrophils induced by G-
CSF and GM-CSF treatment: differential effects and clinical
implications. Leukemia 11:466–478
Waddell ID, Burchell A (1991) Transverse topology of glucose-
6-phosphatase in rat hepatic endoplasmic reticulum.
Biochem J 275:133–137
Wendel U, Schroten H, Burdach S, Wahn V (1993) Glycogen
storage disease type Ib: infectious complications and meas-
ures for prevention. Eur J Pediatr 152, suppl 1:S49–S51
